Business Context and Reporting Period
This Form 8-K is filed by Onconova Therapeutics, Inc. (ONTX) for the reporting period ending December 4, 2019. The registrant is a Delaware corporation listed on The Nasdaq Capital Market. Note: The request metadata references "Traws Pharma, Inc.," but the filing text explicitly identifies the registrant as Onconova Therapeutics, Inc.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, or margin data. The only specific financial metric disclosed is stockholders' equity.
- Stockholders' Equity: Approximately $(6.0) million as of September 30, 2019.
- Minimum Bid Price: Failed to maintain the required $1.00 per share closing bid price.
Material Changes and Listing Status
The Company faces two significant compliance issues with Nasdaq listing standards:
- Minimum Bid Price Deficiency: On December 4, 2019, Nasdaq notified the Company of non-compliance with Listing Rule 5550(a)(2) due to a closing bid price below $1.00. The Company has a 180-day grace period until June 1, 2020, to regain compliance by maintaining a $1.00 bid price for 10 consecutive business days.
- Stockholders' Equity Deficiency: As of September 30, 2019, the Company failed to meet the $2.5 million minimum stockholders' equity requirement. A hearing is scheduled for December 19, 2019, where the Company may request an additional 180-day extension to regain compliance.
- Public Reprimand: On December 5, 2019, Nasdaq Staff advised the Company of an intent to issue a public reprimand regarding a recent public offering (Registration No. 333-234360), citing potential non-compliance with Rule 5635(d).
Outlook, Risks, and Unusual Items
Collaboration: On December 5, 2019, the Company entered into a Pre-approval Access Program collaboration with Inceptua Medicines Access.
Risks and Contingencies:
- Delisting Risk: If the Company fails to regain compliance within the allotted periods (including potential extensions), its common stock will be subject to delisting.
- Remediation Options: The Company may need to effect a reverse stock split to cure the minimum bid price deficiency during a second compliance period.
- Uncertainty: There is no assurance the Company will be able to regain compliance with Nasdaq listing criteria.
Investor Verification Checklist
- Verify the current closing bid price of ONTX to assess progress toward the $1.00 threshold.
- Monitor the outcome of the Nasdaq Hearings Panel scheduled for December 19, 2019, regarding the stockholders' equity deficiency.
- Review the details of the public reprimand letter regarding the Form S-1 offering.
- Confirm the terms and potential financial impact of the collaboration with Inceptua Medicines Access.
- Check for any announcements regarding a reverse stock split or other capital restructuring.